In vItro-DIagnostIcs - Zentrum für Molekulare Diagnostik und

Transcription

In vitro-Diagnostics
in the Capital Region Berlin-Brandenburg
Germany‘s Capital Region Berlin-Brandenburg
Your Partner for Next Generation in vitro-Diagnostics
Berlin-Brandenburg covers the full range of the biotech and pharma value chain, from substance and process
development to clinical research, production and services.
In vitro-Diagnostics and bioanalytics in Berlin-Brandenburg means:
»» About 20 excellent research institutions focus on the
identification of new biomarkers and new platform
technologies for diagnostic tools.
»» More than 80 small and medium enterprises (SME)
as manufacturer or supplier cover a broad spectrum
of highly innovative diagnostics. Berlin-Brandenburg
develops solutions for next generation in vitro-Diagnostics and bioanalytics like sensor-actor-molecules
and autonomous biosensors, genome-, proteomeand glycan-based multiplex analytics (microarrayand bead technologies) and metabolomics platforms for new biomarker strategies.
Basic Research
Identification of Biomarkers
Genomics/Proteomics/
Glycomics/Metabolomics
Product
Production
Approval
Reimbursement
Marketing
»» Berlin-Brandenburg is the place for implementing
clinical validation studies. Germany`s most diversified hospital landscape with the Charité – Universitätsmedizin Berlin has access to patient cohorts of
urban and rural populations of about 180 ethnicities,
covering all medical indications. Customers from research and industry may have access to advanced
biobanking infrastructures.
The Berlin-Brandenburg Center for Molecular Diagnostics and Bioanalytics (ZMDB) is the platform for technology transfer and supports cooperations between science, clinics and industry. The ZMDB is your interface
to get access to Berlin-Brandenburg´s expertise in in
vitro-Diagnostics and bioanalytics.
Applied Research
Validation of Biomarkers
Microarrays · Lab-on-Chip
POCT · Biosensors · Automation
Research &
Development
Clinical Studies
Validation of Biomarkers
Biobanking
Metabiobanking
In vitro-Diagnostics in Berlin-Brandenburg
Selected Companies
1
7
12 13
16 20 40 41
8
42
25
30
29
35
38
33
4
14
31
11 44
23
26
9
15 24
34 36 43
27
22
2
Berlin
6
18 19
21 20
16
32
39
17 28
37
16
3 20
10 45
Brandenburg
5
1 8sens.biognostic GmbH | 2 Alacris Theranostics GmbH | 3 ASTRA BIOTECH GmbH | 4 ATLAS Biolabs GmbH | 5 Attomol GmbH
6 BIOTECON Diagnostics GmbH | 7 BioTeZ Berlin-Buch GmbH | 8 BST Bio Sensor Technology GmbH | 9 caprotec bioanalytics GmbH
10 CellTrend GmbH | 11 Chipron GmbH | 12 CONGEN Biotechnologie GmbH | 13 E.R.D.E.-AAK-Diagnostik GmbH | 14 Epigenomics AG
15 Epiontis GmbH | 16 FILT Lungen- und Thoraxdiagnostik GmbH | 17 GA Generic Assays GmbH | 18 GILUPI GmbH | 19 GlucoMetrix AG
20 Glycotope GmbH | 21 iDoc Institute for Telemedicine and Health Communication GmbH & Co. KG | 22 in.vent DIAGNOSTICA GmbH
23 Institute Cardiac Diagnostics and Therapy (IKDT GmbH) | 24 JPT Peptide Technologies GmbH | 25 Labor Berlin – Charité Vivantes
Services GmbH | 26 LGC Genomics GmbH | 27 Limetec Biotechnologies GmbH | 28 Medipan GmbH | 29 Metanomics Health GmbH
30 MicroDiscovery GmbH | 31 Minerva Biolabs GmbH | 32 peptides&elephants GmbH | 33 PolyAn GmbH | 34 Proteome Factory AG
35 Provitro GmbH | 36 SCIENION AG | 37 Seramun Diagnostica GmbH | 38 SIFIN Institut für Immunpräparate und Nährmedien GmbH
Berlin | 39 Signature Diagnostics AG | 40 Source BioScience imaGenes GmbH | 41 STRATEC Molecular GmbH | 42 Strix Diagnostics GmbH
43 Surflay Nanotec GmbH | 44 TIB MOLBIOL Syntheselabor GmbH | 45 Zentrum für molekulare Onkologie GmbH
Research Institutions
11 12
4
16
6
2
17
5
9
13
Berlin
14 15
1
7
8
20
10
3
18
Brandenburg
19
1 BAM Federal Institute for Materials Research and Testing | 2 Beuth Hochschule für Technik Berlin – University of Applied Sciences
3 DIfE (German Institute of Human Nutrition) Potsdam Rehbrücke | 4 Charité - Universitätsmedizin Berlin | 5 Deutsches RheumaForschungszentrum Berlin | 6 Fraunhofer Institute for Telecommunications Heinrich Hertz Institute | 7 Fraunhofer Institute for Applied
Polymer Research IAP | 8 Fraunhofer Institute for Biomedical Engineering IBMT | 9 Humboldt University of Berlin | 10 IHP GmbH Innovations for High Performance Microelectronics | 11 Leibniz-Institut für Molekulare Pharmakologie (FMP) | 12 Max Delbrück Center
for Molecular Medicine · Berlin-Buch | 13 Max Planck Institute for Infection Biology | 14 Max Planck Institute for Molecular Genetics
15 Max Planck Institute of Colloids and Interfaces | 16 Physikalisch-Technische Bundesanstalt (PTB) | 17 Robert Koch Institute (RKI)
18 Technical University of Applied Sciences Wildau | 19 University of Applied Sciences Lausitz | 20 University of Potsdam
Industry
others
1
Point of Care
Testing
Microbiology
Coagulation
Hematology
Molecular
Diagnostics
Immunoassay
8sens.biognostic GmbH
Alacris Theranostics GmbH
AptaRes AG
ASTRA BIOTECH GmbH
ATLAS Biolabs GmbH
Attomol GmbH
BIOTECON Diagnostics GmbH
BioTeZ Berlin-Buch GmbH
BST Bio Sensor Technology GmbH
caprotec bioanalytics GmbH
CellTrend GmbH
Chipron GmbH
CONGEN Biotechnologie GmbH
E.R.D.E.-AAK-Diagnostik GmbH
Epigenomics AG
Epiontis GmbH
FILT Lungen- und Thoraxdiagnostik GmbH
ifp Institut für Produktqualität GmbH
GA Generic Assays GmbH
GILUPI GmbH
GlucoMetrix AG
Glycotope GmbH
iDoc Institute for Telemedicine and Health Communication GmbH & Co. KG
in.vent DIAGNOSTICA GmbH
Institute Cardiac Diagnostics and Therapy (IKDT GmbH)
JPT Peptide Technologies GmbH
Labor Berlin – Charité Vivantes Services GmbH
LGC Genomics GmbH
Limetec Biotechnologies GmbH
Medipan GmbH
Metanomics Health GmbH
MicroDiscovery GmbH
Minerva Biolabs GmbH
peptides&elephants GmbH
PolyAn GmbH
Proteome Factory AG
Provitro GmbH
SCIENION AG
Seramun Diagnostica GmbH
SIFIN Institut für Immunpräparate und Nährmedien GmbH Berlin
Signature Diagnostics AG
Source BioScience imaGenes
STRATEC Molecular GmbH
Strix Diagnostics GmbH
Surflay Nanotec GmbH
Thermo Fisher Scientific B·R·A·H·M·S GmbH
TIB MOLBIOL Syntheselabor GmbH
Zentrum für molekulare Onkologie GmbH
Clinical
Chemistry
In vitro-Diagnostics in
Berlin-Brandenburg
Overview Companies
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
science
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
others
1
1
Technology
Development
1
1
Assay
Development
Identification
and Validation of
Biomarkers
BAM Federal Institute for Materials Research and Testing
Charité – Universitätsmedizin Berlin
DIfE (German Institute of Human Nutrition) Potsdam-Rehbruecke
Fraunhofer Institute for Telecommunications Heinrich Hertz Institute
Fraunhofer Institute for Applied Polymer Research IAP
Fraunhofer Institute for Biomedical Engineering IBMT
Humboldt University of Berlin · Systems Immunology Lab
IHP GmbH – Innovations for High Performance Microelectronics
Max Delbrück Center for Molecular Medicine · Berlin-Buch
Max Planck Institute for Molecular Genetics
Max Planck Institute of Colloids and interfaces
Physikalisch-Technische Bundesanstalt (PTB)
Technical University of Applied Sciences Wildau
University of Applied Sciences Lausitz
University of Potsdam
Basic Research
Overview Research Institutions
1
1
1
1
1
1
1
1
1
1
1
1
1
Industry
C l i n ic a l C h e m i stry
I m m u n oa ssay
M o l e c u l a r Di ag n ost ics
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
P oi n t o f C a r e T e st i ng
ot he rs
Key figures
11 Foundation: 2000
11 Employees: 10
8sens.biognostic GmbH design, develop and produce
in vitro-diagnostica (IVD) up to CE approval.
We offer: custom-made development and production of
immunochromatographic lateral flow tests and microtiterplate-based assays (ELISAs, etc.) as well as production
of antibody conjugates (colloidal gold, latex, dyes etc.)
for research and production. Our key business activities
also cover novel protein-based macro arrays for multianalyte detection (e. g. panels for heart attack, heart risk and
TORCH) as well as adaptable reader systems for easy quantification of rapid test and macro array results.
Market Segments
11 Lateral flow assays
11 Reader systems for quantification
11 Development on demand
11 IVD-orientated nanotechnology
Contact
Products 1 Technologies
Robert-Rössle-Straße 10
13125 Berlin · Germany
11 Rapid tests
11 QuickSens® h-FABP, cTnI
11 QuickSens® CRP, hs-CRP
11 Reader system QuickSens® Ω100
www.biognostic.de
Volker Landorff
[email protected]
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
11 Foundation: 2008
11 Employees: 15
The company is based on novel translational medicine/
systems biology technology developed at the Max Planck
Institute for Molecular Genetics in Berlin coupled with preferential access to the world’s most cost effective sequencing and genotyping technology.
The scientific founders are among the world’s foremost experts in sequencing technology, systems biology and biomedicine.
Alacris Theranostics offers its services internationally in
Europe and North America.
Contact
11 Cutting-edge next generation sequencing technology
Fabeckstraße 60-62
11 Genome, epigenome, and transcriptome sequencing
11 Proprietary technology platform ModCell™
11 Identification of diagnostic markers
11 In silico simulations for the study and evaluation of
signal pathways relevant for cancer
11 Simulation of drug effects
11 Stratification of cancer patients for their clinical trials
and for biomarker discovery
Major R&D-Topics
11 Biomarker discovery
11 Computer modeling for cancer drug validation
11 Non-invasive cancer genome sequencing
11 Partner in the IT Future of Medicine-project within
the FET Flagship Initiative - Partner in the OncoTrackproject within the Innovative Medicine Initiative
[email protected]
www.alacris.de
Dr. Bodo Lange
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
AptaRes AG
Key figures
11 Foundation: 2002
11 Employees: 18
AptaRes is a leading biotechnology company providing oligonucleotide aptamers as an alternative to common antibodies. AptaRes is the sole owner of the proprietary MonoLex procedure for Aptamer selection and its applications.
We offer high resolution bioanalytics and the technology
for downstream processing for immunoglobulins using an
innovative IgG Fc-specific binder (like protein A). A quality management system ensures transparent, validated and
reproducible processes. The bioanalytical service includes
high resolution 2D-gel electrophoresis, mass spectrometry,
N-terminal Sequencing, functional tests and more. The
protocols are custom tailored to validate product identity,
quantitate side products, and validate processes as well as
binding specificities of antibodies and aptamers.
Market Segments
11 Aptamer selection and applications
11 Bioanalytics
11 Aptamers
11 Antibody Purification
11  Protein Identification / Proteomics
11 N-terminal Sequencing (Edman- Sequencing)
11  2D high Resolution Electrophoresis
11 MALDI-TOF-MS Analytic
11 Structure Validation
11 Host Cell Protein Analysis (HCP-Analysis)
Major R&D-Topics
11 New Aptamer based active agents
11 New Aptamer based applications
Contact
AptaRes AG
Tempelhofer Weg 11-12
Phone +49 30 24537613
Fax +49 30 24537622
[email protected]
www.aptares.de
PD Dr. Andreas Kage (CEO)
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
ASTRA BIOTECH GmbH
Key figures
11 Foundation: 2009
Astra Biotech GmbH is a quality-focused company with its
success founded on dependable science and strong relationships to develop IVD-compliant, CE-labelled in vitrodiagnostic assays for laboratories specialising in multimedical fields or in education. The product range available
includes reagents for detecting and calibrating human hormones, genetic diseases, tumour markers, allergens, antibodies, and recombinant proteins.
Market Segments
Major R&D-Topics
11 IVD
11 Research on brain stroke, heart attack treatment and
11 Molecular diagnostics
bone fracture repair
11 Immunoassays
11 Stem cells in treatment of different diseases
Contact
ELISA, PCR, MICROARRAY-on-a-CHIP
ASTRA BIOTECH GmbH
Im Biotechnologiepark · TGZ I
14943 Luckenwalde · Germany
11 Hormonal diagnostics, metabolism, fertility,
pre- and neonatal
11 Tumourmarker
11 Anaemia (Ferritin)
11 Allergy (IgE- total and specific),
11 Osteoporosis, thrombosis, sensitivity towards
anticoagulants, sensitivity to antidepressants
11 TORCH, HIV, niche diseases
11 Conjugates, calibrators, recombinant proteins,
antigens, allergens
Phone +49 3371 681 450
Fax +49 3371 681 451
[email protected]
www.astrabiotech.de
Anna Fot (Business Manager)
Alexandra Ghica-Cantacuzino (International Sales
and Marketing)
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
atlasbiolabs
ot he rs
ATLAS Biolabs GmbH
Key figures
11 Foundation: 2006
11 Employees: 12
ATLAS Biolabs GmbH is a leading provider of complex
analyses in molecular genetics including microarray-based
genomic services, targeted sequence capture, and next
generation sequencing.
Market Segments
ATLAS Biolabs performs
11 Genome-wide gene expression and SNP analyses
11 Array CGH
11 Comprehensive mutation profiling and other novel
NGS applications
for academic institutions, pharmaceutical and biotechnological enterprises, as well as for clinicians and registered
doctors.
The following services are provided by ATLAS Biolabs:
11 Exome enrichment
11 Next generation sequencing
11 Genotyping
11 Expression profiling
11 Whole genome human SNP genotyping
11 Molecular karyotyping
11 Targeted sequence enrichment
11 Raindance sequence enrichment
11 Sample preparation
11 Bioinformatics analysis and project management
11 Methylation
11 Oncocarta
Contact
ATLAS Biolabs GmbH
Friedrichstraße 147
Phone +49 30 3198966 0
Fax +49 30 3198966 19
[email protected]
www.atlas-biolabs.com
Prof. Dr. Peter Nürnberg (CEO)
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
1
1
1
1
1
1
1
1
Attomol GmbH
Key figures
11 Foundation: 1997
11 Employees: 12
Development, production and distribution of IVD-marked
diagnostic tests under Attomol brand or OEM
11 Main technologies are protected by 5 patents
11 Direct marketing in Germany
11 Formation of an international distributor network is not
yet finished
11 Co-founder of the research community BioResponse e.V.:
www.bioresponse.de
Market Segments
11 Molecular genetics
11 Molecular diagnostics of pathogens
11 Autoimmunodiagnostics
Major R&D-Topics
11 Technologies:
LoopTag real time PCR or DNA-LINA strip tests:
Mycobacteria, Bordetella, Borrelia, Mycoplasma
11 Applications:
Real time PCR, multiplex technologies, bead assay
Anti-lipid antibody detection, coagulation risk profiling
11 Quicktype mutation assays: Thrombophilia, drug
metabolism, lactose intolerance etc.
11 Bead Assay: 11plex Anti-Nuclear-Antibody confirmation
11 Antibody LINA strip tests: Anti-gangliosides,
anti‑phospholipids
Contact
Attomol GmbH
Schulweg 6 · OT Lipten
03205 Bronkow · Germany
www.attomol.de
Dr. Werner Lehmann
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
Our company focuses on the development of rapid and innovative detection systems for pathogenic, spoilage and
genetically modified organisms based on real time PCR.
Besides detection kits, the foodproof product line also includes kits for sample preparation.
Today, as an international biotechnology company, BIOTECON
Diagnostics develops, produces and markets these products. We foster a growing network of distributors as well
as offer contract development and production to other biotech companies.
Due to strong partnerships with food, beverage and pharmaceutical companies, BIOTECON Diagnostics is well aware
of their current and future problems. Our experience lends
to our strong capability to find new and economically
interesting approaches to these existing and upcoming
problems both in production and processing. As a small
company, we maintain our flexibility to respond to industry concerns quickly and efficiently. Simply put, we provide
desired solutions.
©Fotolia · Sven Hoppe
BIOTECON Diagnostics was founded in 1998 and currently
has 51 employees. Our expertise is microbiological service
testing of food, beverage and pharmaceutical products.
Contact
Hermannswerder 17
14473 Potsdam · Germany
Phone +49 331 2300 00
Fax +49 331 2300 299
[email protected]
www.bc-diagnostics.com
Kornelia Berghof-Jäger, Ph. D. (CEO)
Alois Schneiderbauer (CBO)
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
11 Foundation: 1992
11 Employees: 20
We understand ourselves as partners of biotechnological
research, pharmaceutical industry and lab analysis for innovation and quality. Our Business Portfolio:
11 In vitro-diagnostics: e. g. for therapeutical antibodies
(TAB) to measure the interaction between TAB and
antigens to optimize the treatment
11 Customized synthesis of oligonucleotides
(high level services)
11 Support of mycotoxine and vitamin analysis; production
of very effective immunoaffinity columns, ELISAs, and
toxin and detection conjugates
11 ELISA development, conjugation and labeling of
biomolecules, other services
11 Signal/Assay enhancement using our high-tech molecule
(Polystrept R), e. g. for lateral flow tests
Market Segments
11 IVD development and production
11 Oligonucleotid synthesis
11 Immobilization of molecules
11 ELISA development
11 Feed and food analysis
Outstanding expertise in immunoassays.
Own patents and IP:
11 Signal enhancement by Polystrept R (highest
immobilization, outstanding biotin binding capacities)
11 Coating of surfaces for binding biotinylated molecules
11 Unique IVD technology for measuring therapeutic
antibodies and antigen in patient serum
11 Immobilisation of biomolecules, e. g. on surfaces and
columns
Major R&D-Topics
11 IVD development for the therapeutic antibodies:
Enbrel, Avastin, Herceptin
11 Aptamere development
Contact
Haus 79 · Robert-Rössle-Straße 10
Phone +49 30 94892130
Fax +49 30 9494509
[email protected]
www.biotez.de
Uwe Ahnert (Member of the board)
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
1
1
1
1
1
1
1
1
Thermo Fisher Scientific, B·r·a·h·m·s GmbH
Key figures
Thermo Scientific B·R·A·H·M·S Biomarkers investigate, develop and manufacture novel diagnostic testing procedures
to improve early diagnosis and treatment of life threatening
diseases. With our high-quality immunodiagnostic tests for
sepsis, cardiovascular, pulmonary, and cancer disorders as
well as prenatal screening we contribute to the creation of
a healthier future – to the greatest advantage for medical
professionals and patients.
In Future simple and economic blood tests will be of great
importance for an early detection and successful treatment
of diseases. With our Know-How and technologies we are
confident to play an active role in this future: Our products
provide important information to clinicians and laboratories in more than 65 countries worldwide and support their
clinically and economically relevant decisions.
On the basis of our completely owned patents and with
help of more than 470 employees worldwide Thermo Scientific B·R·A·H·M·S Biomarkers are leading in specific market places and therapeutic areas.
11 Fully automated KRYPTOR® platform with TRACE®
technology (TRACE = Time-Resolved Amplified Cryptate
Emission)
11 Radioimmunoassay
11 Lumineszenzassay
11 Enzymimmunoassay
Major R&D-Topics
The aim of our basic research is to identify new biomarkers,
with support by international cooperations and reputable
research institution.
Contact
Thermo Fisher Scientific
B·R·A·H·M·S GmbH
Neuendorfstraße 25
16761 Hennigsdorf · Germany
Phone +49 3302 8830
Fax +49 3302 883100
[email protected]
www.thermoscientific.com/brahms
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
11 Foundation: 1991
11 Employees: approx. 20
BST’s history dates back to 1975 when a biosensor research group started at the Berlin Academy of Sciences.
Already in 1982 the first European glucose analyzer based
on a multi-way glucose biosensor could be launched successfully.
Today, BST is market leader in multi-way biosensors in
Europe and an international operating company in e. g.
Asia, Eastern and Western Europe.
BST’s core competence is the development and production
of multi-way biosensors as well as instruments based on
these multi-way biosensors for laboratory and POCT applications. In addition to that also all related consumables are
developed, produced and marketed by BST.
Major R&D-Topics
11 Development of potentiometric sensors based on
thick film technology
Market Segments
11 POCT diagnosis of glucose and other metabolites based
on multi-way biosensors
11 Determination of glucose and other metabolites for
clinical chemistry
11 Diagnosis of training state of athletes (lactate analysis)
11 Immobilising of biological recognition elements for
usage in diagnostic tools
11 Conception, development and production of:
11 Multi-way biosensors for pmol/l to mmol/l
concentrations
11 Instruments based on multi-way biosensors
(e. g. GLUKOMETERPRO, LACPRO, LabTrend)
11 All related consumables for the application of
multi-way biosensors
11 Development of minimal invasive glucose system
Contact
Buchholzer Straße 55 – 61
Phone +49 30 7676731 0
Fax +49 30 7676731 28
[email protected]
www.bst-biosensor.com
Dr. Dorothea Zahn (Managing Director)
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
11 Foundation: 2006, start of building up operation
in 2008
11 Employees: 30
caprotec bioanalytics GmbH has developed a ground-break
ing, proprietary technology to reduce the complexity of
protein mixtures and samples in a targeted and directed
manner.
11 caprotec’s Capture Compound Mass Spectrometry
(CCMS) Technology is based on trifunctional Capture
Compounds™ which enable capturing and isolating
proteins based on their functionality
11 CCMS is closing a technology gap between shotgun
approaches and pull-down experiments – thus
addressing an unmet need in the proteomics community
11 The company is commercializing the CCMS technology
as kits for research applications and customized
Capture Compounds in collaborations with
pharmaceutical companies or academic research
11 The focus is on investigating mechanisms of drug action
and avoidance of toxicological effects of small molecule
drugs
Major R&D-Topics
11 Small molecule – protein interactions
11 Proteomics
11 Signal transduction
11 Protein kinases
Market Segments
Contact
11 Drug discovery
Volmerstraße 5
11 Proteomics research
www.caprotec.com
Prof. Dr. Hubert Köster
Capture Compound Mass Spectrometry (CCMS)
11 caproKits™
11 caproBox™
11 caproMag™
11 ImproMed
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
CellTrend GmbH
Key figures
11 Foundation: 1998
11 Employees: 8
CellTrend is a certified biotech and diagnostic company.
We are offering services and products:
11 Bioassays for drug research and development
11 Cell culture testing
11 Immunogenicity testing
11 Development and production of immunoassays
Contact
Market Segments
11 Pharma/Biotech/Cosmetics
11 Contract research
11 Contract analysis
11 Contract production
11 Diagnostics
11 Mammalian cell culture
11 Immunoassays for research and diagnostic
Major R&D-Topics
11 Oncology
11 Cardiovascular diseases
11 Detection of autoantibodies
11 Biomarker development
CellTrend GmbH
Im Biotechnologiepark · TGZ 2
Phone +49 3371 681 290
Fax +49 3371 681 312
[email protected]
www.celltrend.de
Dr. Harald Heidecke (CEO)
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Chipron GmbH
Key figures
11 Foundation: 2004
11 Empoyees: <15
Chipron GmbH develops and manufactures DNA macro
arrays on polymer supports. The company specializes
in assay development for pathogen detection, mutation
analysis and food analysis based on its proprietary LCDArray platform.
LCD-Array Kits for HPV typing, kras mutation analysis, detection of fungal or bacterial pathogens and meat species
identification are distributed in over 15 countries through
a network of distribution partners.
Apart from catalogue products Chipron offers customized
LCD-Array Kits for particular demands and has developed
over 100 of such assays during the last 5 years for industrial and governmental customers. LCD-Array Kits are
available as RUO or CE-IVD kits and as OEM products on
demand.
The minimal requirements for specific lab instrumentation
in combination with the simple but comprehensive data
readout by the SlideReader software make LCD-Arrays a
very robust and economical solution for virtually any laboratory with experience in PCR.
major R&D-Topics
11 DNA/PCR-based quick tests
Contact
Chipron GmbH
Eresburgstraße 22 – 23
Phone +49 30 78799470
Fax +49 30 78799499
Market Segments
DNA-based detection assays for human or veterinary
pathogens, mutation analysis and food analysis
11 PCR-based DNA macroarray kits for pathogen, species
and mutation detection
11 Non fluorescent data readout by transmission light
scanning and slidereader software
11 Scanner, centrifuge and analysis software
[email protected]
www.chipron.com
Dr. Volker Heiser
[email protected]
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
11 Foundation: 1998
11 Employees: > 25
CONGEN is specialized in food testing by molecular analysis based on DNA and RNA detection. CONGEN has been a
pioneer for over a decade in the development and application of food and feed analysis by real time PCR. Due to our
experience in this field, we have a worldwide unmatched
competence. We are offering a complete package consisting of:
11 Providing fully accredited service
11 Full range of real time PCR kits for every real time
PCR cycler
11 Full range of kits and protocols for sample preparation
11 Real time PCR core reagents (SureMaster and
SureCyle®)
11 Real time PCR training and full support for real time PCR
laboratory
Our mission is to serve the food industry with an excellent
service and with standardized and reliable test kits in order
to realize highest possible food safety and food quality.
The full spectrum of our analytical services and products is
integrated in our program called:
SureFood®
The SureFood program covers parameters in the application of GMO, allergen, pathogen, animal, plant detection.
In all the above application fields CONGEN is an internationally highly recognized and accepted partner for service
and real time PCR reagents. The quality of the analyses is
assured by using validated methods. CONGEN is accredited
according to the EN ISO 17025:2005. All kits are manufactured according to the ISO 9001:2008.
Contact
Robert-Roessle-Straße 10
Phone +49 30 948935 00
Fax +49 30 948935 10
[email protected]
www.congen.de
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
11 Foundation: 2005
E.R.D.E.-AAK-Diagnostik GmbH is a diagnostics laboratory
that offers the detection of diverse autoantibodies (agAAB)
in sera.
Agonistic autoantibodies (agAAB) are directed against
cellular receptors, particularly those involved in heart function, blood pressure regulation and vascular diseases.
AgAAB are frequently detected in patients with:
11 DCM, Myocarditis:
agAAB against β1-adrenergic receptor and
M2-muscerinergic receptor
11 Hypertension:
agAAB against α1-adrenergic receptor
11 Diabetes type 2:
agAAB against α1- and AT1-adrenergic receptor
11 Dementia:
agAAB against α1- and β2-adrenergic receptor
To determine the agAAB-status different special analysis
techniques are used. The prevalence of the different agAAB
in the different diseases varies from 30 to 90 %.
Patients will benefit – at a given agAAB indication – from
a personalized, specific medicamentous therapy, which accounts for the agAAB induced malfunction of receptors.
The detection of the agonistic Autoantibodies (agAAB) is
realized by the following analysis techniques:
11 ELISA (not functional):
Detection of a single agAAB
11 BIOASSAY (functional):
Analysis of all agAAB of the sample
11 CALCIUM (functional):
Measurement of intracellular calcium transients
Contact
Biomedizinischer Forschungscampus Berlin-Buch
Phone +49 30 9489 2226
Fax +49 30 9489 2229
Mobile+49 1607537115
[email protected]
www.aak-diagnostik.de
Mrs. Dipl.-Ing. Marion Bimmler
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Epigenomics AG
Key figures
11 Foundation: 1998
11 Employees: 82
Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of proprietary products
for cancer.
The Company’s products enable doctors to diagnose cancer
earlier and more accurately, leading to improved outcomes
for patients.
Epigenomics’ lead product, Epi proColon, is a blood-based
test for the early detection of colorectal cancer, which is
currently marketed in Europe and is in development for the
US.
The Company’s technology and products have been validated through multiple partnerships with leading global
diagnostic companies including Abbott, QIAGEN, Sysmex,
and Quest Diagnostics.
Epigenomics is an international company with operations
in Europe and the US.
11 Epi proColon (marketed in EU; in R&D for US)
11 Epi proLung (marketed in EU)
11 Pipeline with further products for colorectal, lung
and prostate cancer
11 Applications in early detection, diagnosis, prognosis,
and drug response prediction
11 All products based on proprietary DNA methylation
technology
Major R&D-Topics
11 Biomarker discovery and validation
11 IVD development for EU and US (ISO 13485)
11 Companion diagnostics R&D for pharma partners
11 DNA methylation technologies
Contact
Epigenomics AG
Kleine Präsidentenstraße 1
Phone +49 30 24345 0
Fax +49 30 24345 555
[email protected]
www.epigenomics.com
Dr. Achim Plum (Sen. VP Corporate Development)
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
1
1
1
1
1
1
1
1
Epiontis GmbH
Key figures
11 Foundation: 2003
11 Employees: 11
Using a novel molecular diagnostics technology, Epiontis
offers an immune cell monitoring service as well as customized development of epigenetic assays.
Market Segments
11 Quality control for cell therapies
11 Immunomonitoring
11 Epigenetic markers
11 Biomarkers
Major R&D-Topics
11 Discovery of novel epigenetic markers
11 Markers specific for particular cell types
11 Future diagnostic (prognostic, predictive, monitoring)
markers
11 Immunomonitoring service (fee for service)
based on epigenetic markers for immune cells
11 Assays for cell therapy quality control
(contract development)
Contact
Epiontis GmbH
Rudower Chaussee 29
Phone: +49 30 6392 3474
[email protected]
www.epiontis.com
Ulrich Hoffmüller (PhD, MBA, Chief Business Officer)
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
1
1
1
1
1
1
1
1
Key figures
11 Foundation: 1992
11 Employees: 7
FILT – Lung- and Thorax Diagnostic GmbH – is developer and
manufacturer of products with focus on ‘Exhaled Breath
Analysis’ and airways inflammation diagnostic for treatment management in Asthma and COPD.
Our mission in FILT is to use the combined experiences in
medical functional and laboratory diagnostic to generate
innovative products to improve the early diagnostic of inflammatory diseases and its therapeutic management.
Market Segments
Major R&D-Topics
11 Pulmonology
11 POCD of inflammatory diseases
Lung function diagnostic, specialized in fractionated breath
collection and measurement of flows, volumes, pressures,
gases and biomarkers for analytical evaluation of inflammatory diseases
Contact
11 ECoScreen 2 (EBC Collector F)
Robert-Rössle-Straße 10
11 Asthma
11 COPD
11 ECoCheck (EBC Analyser for H2O2, pH, Lactat)
Phone +49 30 94892114
Fax +49 30 94892115
[email protected]
www.filt.de
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
1
1
1
1
1
1
1
1
Key figures
11 Developing, manufacturing and distributing in vitro-
diagnostic assays in the field of systemic autoimmunity
like rheumatic diseases, autoimmune hepatitis,
autoimmune neuropathies, vasculitis, autoimmune
kidney diseases, gastroenterology and antiphospholipid syndrome (APS)
11 Market leader for anti-asialoglycoprotein receptor ELISA
(anti-ASGPR) (autoimmune hepatitis)
11 Inventor and market leader for APS antibody profiling by
immunodot
11 Inventor and market leader for anti-glycoprotein 2
ELISA (GP2) a new serological marker for Crohn’s
disease
11 Manufacturing cell-based immunofluorescence assays
like HEp2 cells, ANCA and Crithidia luciliae cells
11 Operating worldwide
Major R&D-Topics
11 New diagnostic markers for autoimmune neuropathies
11 New diagnostic marker for gastroenterology
Market Segments
11 In vitro-diagnostics
11 IFA (HEp2 cells, ANCA, Crithidia luciliae cells
and tissue sections)
11 ELISA
11 Immunodot
11 Rapid tests
11 Latex tests
Contact
Ludwig-Erhard-Ring 3
15827 Dahlewitz/Berlin · Germany
Phone +49 33708 9286 0
Fax +49 33708 9286 50
[email protected]
www.genericassays.com
Dr. Christina Fritz (Head of Scientific Marketing)
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
1
1
1
1
1
1
1
1
GILUPI GmbH
Key figures
11 Foundation: 2006
11 Employees: 18
11 Several collaborations with various national
and international medical universities
11 International company with operations in Europe
and the US
11 Several positive ethical votes for clinical trials
11 Proof of concept in vivo
11 Awarded for a grant “Medizintechnik –
Innovationswettbewerb 2007” of the BMBF
Market Segments
Major R&D-Topics
The inventions of the GILUPI GmbH are in the market area
of molecular diagnostics. In the prenatal sector the market
for screening for trisomy 21 is about 2,5 billion EURO. In
the field of cancer for isolating rare tumorcells the market
is about 1 billion EURO.
11 Development of the functionalized structured medical
wire (FSMW)
11 Development of antibodies
Contact
GILUPI GmbH is developing, marketing, and selling innovative new nanotechnology-based medical devices to detect
and monitor circulating rare blood cells, with a strong focus
on the prenatal diagnostic and cancer diagnostic market
11 One application of the new nanodetector device is
in the area of prenatal diagnosis, e. g. for analysis of
chromosomal aberrations such as that found in Down
syndrome
11 Another application is focusing on detecting and
enriching rare circulating tumor cells (CTC) from the
peripheral blood of cancer patients as markers of
disease recurrence and efficacy of systemic cancer
treatment
Bild: © Michael Kempf (fotolia.com)
GILUPI GmbH
Am Mühlenberg 11
Phone +49 331 58184782
www.gilupi.de
Inga Kliem
[email protected] Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
GlucoMetrix AG
Key figures
11 GlucoMetrix AG
was founded in 2001. It has 3 major subsidiaries that
concentrate on different aspects of enhancing the
quality of life for people suffering from diabetes.
11 GlucoMetrix NIB GmbH
develops medical devices for measuring blood sugar
non-invasively, i. e. without puncturing the skin.
11 GlucoMetrix PVS GmbH
develops a new production method for insulin which
promises a purer insulin with less side effects.
11 GlucoMetrix Pharma VV GmbH
develops, manufactures and markets medicinal
products related to wound healing. These are
particularly suited for diabetic wounds.
Major R&D-Topics
11 Opto-acoustical device to measure blood sugar
11 Development of expression platforms for
biomedical products
11 Development of downstream purification methods
non‑invasively (in collaboration with ETH Zurich)
11 Immunological assay to determine glycated serum
proteins (POC-assay; in collaboration with FHI BMT)
11 Genetic predisposition for diabetes mellitus
11 Cost-effective production methods for human insulin
11 BIOSept line of wound treatment products
Contact
GlucoMetrix AG
Am Mühlenberg 11
[email protected]
www.glucometrix.de
P.P. Schikora (CEO)
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Glycotope GmbH
Key figures
11 Foundation: 2001
11 Employees: 75
GLYCOTOPE is a leading biopharmaceutical company in the
fields of glycomics and immunotherapeutics and one of the
rare full service providers in the development of biologics.
For proprietary and customers’ drug development programs Glycotope has established a business unit to perform immunomonitoring of clinical samples. Offered also
as a stand-alone service to support clinical studies, the
pharmacokinetic and – dynamic characteristics of biotherapeutics and the immune status of patients are determined
according to the GCLP guidelines.
A variety of kits for quantitative characterization of the
cellular immune status and responses is provided by Glycotope-Biotechnology. The kits are used by lab physicians,
clinical research organisations and pharmaceutical R&D
departments to better understand the activity of a number
of immune cells that are relevant in a variety of diseases
www.glycotope-bt.com.
Contact
11 Design and conduct of immunomonitoring assays to
Glycotope GmbH
support clinical development
11 Diagnostic test kits based on flow cytometry procedures
to measure various cell functions for functional
characterisation of cellular immune response, T-cell
analysis and characterisation of haematological relevant
autoimmune diseases
Major R&D-Topics
11 Continuous development of project specific
immunomonitoring assays
Phone +49 30 9489 2600
Fax +49 30 9489 2609
[email protected]
www.glycotope.com
Dr. Hans Baumeister (Associate Director Clinical
Immunomonitoring)
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
iDoc Institute for Telemedicine and Health Communication GmbH & Co. KG
Key figures
11 Founded 2004
iDoc provides innovative solutions within the fields of telemedicine. The institute combines medical expertise with
professional IT and communication management.
Market Segments
11 Telemedicine
11 Telesomnology
11 Telemonitoring
Contact
11 Healthcare networks
11 Dementia care
11 Telemedical screening for sleep apnea
11 Telemedical monitoring for diabetes,
metabolic syndrom
11 Telemedical data exchange application
11 Telemedical network for multicenter studies
11 Telemedical care support for dementia
Major R&D-Topics
11 Telemedicine
11 Prevention
11 Comprehensive medical services
iDoc Institute for Telemedicine and
Health Communication GmbH & Co. KG
Posthofstraße 8
www.idoc.de
Prof. Nikolaus Boehning
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
11 Founded 2004
11 Employees: 100
ifp Institut für Produktqualität GmbH is an independent
competence centre for food, feed and pharmaceutical analytics, offering a complete range of services and diagnostic
products. The combination of expert staff, state-of-the-art
laboratory equipment and food diagnostics specifically
developed and produced by ifp guarantees high-quality
analyses and competent service. Several of ifp’s innovative
product lines are being successfully distributed worldwide
by renowned cooperation partners.
11 Microbiological test kits for the microtiter plate based
determination of all water-soluble vitamins in food,
pharmaceuticals and human serum
11 Real-time PCR kits for the detection of food pathogens,
GMO, allergens, plant and animal species
11 Immunological assays for the rapid on-site detection
and quantitative determination of food allergens
11 Microtiter plate based enzymatic test kits for the
photometric determination of sugars, organic acids and
other metabolites in food
Major R&D-Topics
11 Development of improved bioanalytical methods for
food testing purposes
11 1 Strong involvement in funded research projects
Contact
Teltowkanalstraße 2
Phone +49 30 7668600
Fax +49 30 76686050
[email protected]
www.produktqualitaet.com
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
1
1
1
1
1
1
1
1
Key figures
Your Service Provider for Human Diagnostics
11 Biomaterials of human origin
11 Enhanced biobanking
11 Protein chemistry
11 Contract-based development of proteins and
diagnostic tests
11 Clinical studies and CE marking procedures for IVD
Market Segments
in.vent supplies you with
11 Clinically defined sera and plasma with a worldwide
unique variety of matrices
11 Clinically defined human biomaterials like
synovial fluid, CSF, etc.
Major R&D-Topics
11 Stool, faecal samples
11 Various tissues
11 A great variety of proteins
11 Services in development and manufacturing
of diagnostic tests
in.vent meets your individual requirements for the complete
value chain which involves the areas of R&D, production
and quality control with a strictly emphasis on reliability,
quality and adherence to schedules.
Contact
11 in.vent’s procurement of human biomaterial is always
Neuendorfstraße 17
16761 Hennigsdorf · Germany
strictly oriented towards individual projects as well
as highest ethical standards and superior quality.
All materials are procured exactly with the information
you need and on your specific demand.
11 in.vent’s enhanced biobanking serves you with clinically
characterized human biomaterials that match exactly
your needs to build your customized biobank.
11 in.vent’s newest products are the execution of the
laboratory part of clinical studies and of CE marking
procedures.
We would be delighted finding solutions that fit you.
Phone +49 3302 55199 11
www.inventdiagnostica.de
Dr. J.-M. Hollidt (Managing Director)
[email protected]
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
11 Foundation: 2002
11 Employees: 8
IKDT is a leading laboratory worldwide in differential diagnostics of viral infections and inflammation of heart muscle
tissue following the international recommendations.
Three main topics will be covered for routine diagnostics:
11 Histology
11 Immunohistochemistry and
11 Molecular virology
IKDT is the only cardiological laboratory performing mole
cular diagnostics of endomyocardial biopsies in Germany
which is accredited by College of American Pathologists
(CAP) according to FDA guidelines. Customers for our biopsy diagnostics are hospital-affiliated institutions or private
doctor offices.
By its platform Innovative Diagnostics IKDT lab as one of
the first service providers in Europe offers for customers
the prompt access to two innovative research technologies – and Taqman Low-Density-Arrays (Applied Biosystems) for gene expression studies or microRNA profiling,
and bead-based Luminex technology for multiplex measurement of cytokine and immunological profiles.
Market Segments
11 Molecular diagnostics and research in cardiology
Services provided:
11 Routine differential diagnostics of endomyocardial
biopsies on cardiomyopathies
11 Molecular diagnostic service
Major R&D-Topics
11 MicroRNA profiling in myocardial tissue and
peripheral blood
11 Gene expression studies in cardiac patients
11 Autoantibodies in cardiac patients
11 Mutation screening in patients with cardiomyopathy
Contact
Moltkestraße 31
[email protected]
www.ikdt.com
www.innovative-diagnostics.eu
Dirk Lassner, PhD (Managing Director)
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
1
1
1
1
1
1
1
1
Key figures
11 Foundation: 2004
11 Employees: 45
11 Offices: Berlin, Boston, Brussels
11 Collaborations: NIH, Duke University, Harvard Medical
School (USA), Karolinska Institutes (Sweden),
BioNTech AG (Germany)
JPT Peptide Technologies (JPT) is an ISO 9001:2008 certified and GCLP audited global supplier and development
partner for innovative peptide related immune m
onitoring
tools, molecular diagnostics and biomarkers. JPT has de
veloped several high-content peptide technologies that
allow proteome spanning and multiplexed discovery, validation, quantification of biomarkers as well as monitoring
humoral and cellular immune responses in disease progression and under therapeutic invention.
Major R&D-Topics
11 Seromarker discovery, validation and quantification
11 Development of diagnostic tools for immune monitoring
and patient stratification
11 Peptide discovery, qualification and optimization
Market Segments
Contact
11 Molecular and immune diagnostics
Volmerstraße 5
11 Vaccine and immunotherapy development
11 PepStar
TM
Peptide microarray platform for seromarker discovery
and immune monitoring
11 PepSpotTM
Ultra high-throughput peptide synthesis approach for
proteome wide T-cell epitope discovery
11 PepMixTM
Peptide pool platform for profiling cellular immune
responses
11 SpikeTidesTM
Small scale peptide technique for biomarker
quantification
Phone +49 30 6392 5500
Fax +49 30 6392 5501
[email protected]
www.jpt.com
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
11 Foundation: 2011
The company is the service subsidiary of Europe’s largest
hospital laboratory for clinical pathology and offers complete solutions for any kind of testing for the ivd industry,
CROs, the pharmaceutical industry, life science companies
and research facilities.
Labor Berlin performs > 20 Mio analyses in clinical pathology per year; it is the exclusive laboratory partner of
Charité Universitätsmedizin Berlin and the Vivantes Network for Health and provides the diagnostics for approximately 9.000 in-house patients a day and over 800.000
out-patients per year.
Contact
11 Very broad portfolio of routine diagnostic testing
Augustenburger Platz 1
11 Individual patient services (health monitoring)
11 Testing of new preclinical diagnostics systems
(prototypes)
11 High throughput testing under routine conditions of
novel diagnostic platforms
11 Co-development of new biomarkers with industrial
partners
11 Validation of new bioassays for ivd industry
11 Design, realization and analysis of clinical studies for
CROs, pharmaceutical industry, life science companies
and research facilities
11 Field tests of telemedical IT solutions
Major R&D-Topics
11 Co-developing and establishing a fully automated
platform for microbiological pathology
11 Data collection on preanalytical systems
11 Co-developing and establishing a routine
tele‑haematological IT solution for linking
12 hospitals in Berlin
www.laborberlin.com
Dr. Andreas Weimann
[email protected]
Florian Kainzinger
[email protected]
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
LGC Genomics GmbH
Key figures
11 Foundation: 1993 as AGOWA
11 LGC Group acquires AGOWA in 2005
11 Rebranded and established in April 2010 as LGC
Genomics
11 Number of employees: 50
A division of the LGC Group, LGC Genomics delivers high
quality services and products for DNA and genetic analysis
and sample preparation including:
11 Next generation sequencing
11 DNA sequencing and library construction
11 Nucleic acid extraction services
11 DNA extraction products
11 pharmacogenetics and diagnostic services.
LGC is an international science-based company and market
leader in analytical, forensic and diagnostic services and
reference standards.
Market Segments
11 Pharmaceutical and biotechnical companies
11 Private and public research organisations
11 Medical institutions
Genomic services:
11 Next generation sequencing (Roche/454 and Illumina
HighSeq 2000)
11 Re-sequencing of genes and/or genomic regions
11 Library services
11 Cloning and sequencing
11 Identification of microorganisms
11 Genotyping services
11 Sanger DNA sequencing services
Nucleic acid preparation:
11 Nucleic acid extraction service (DNA, RNA)
11 Kits for nucleic acid preparation (medium/high
throughput)
Contact
LGC Genomics GmbH
Ostendstraße 25
Phone +49 30 5304 2200
Fax +49 30 5304 2201
[email protected]
www.lgcgenomics.com
Dr. Steffen Krüger (Managing Director)
Werner von Heimann (European Sales and
Marketing Manager)
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
11 Foundation: 2001
11 Employees: 20
11 Software development
11 System integration
11 Diagnostics for infectious diseases
11 Analysis of genetic predisposition
Market Segments
11 Infectious diseases
11 Pharmacogenomics
11 Cardiology
11 Biomarker identification and validation
Major R&D-Topics
The company develops modern biomolecular methods and
has brought already more than thirty innovative products
on the market (CE marked products).
11 Close-partnered – project TERA-Diagnostic
11 High-speed and high-quality proof systems for the
detection of bacteria and viruses
11 Proof system for allelic discrimination detection for
hereditary diseases
11 High-sensitive and secure immunoblot for early
detection of Lyme disease
Software and device
11 Creation of affordable communication solutions which
connect ambulatory (out-patient) and stationary
(in‑patient) care
11 Limetec has developed lab@ccess, an innovative webbased platform for laboratory orders. This innovative
system provides versatile information, supports data
exchange with the lab and makes cost transparency
possible by allowing analyses of economic indicators.
11 MRSA detection
11 Allelic discrimination assays (TaqMan method)
11 Detection of human antibodies against Borrelia
11 Drug resistance of Mycobacterium tuberculosis Contact
Ladeburger Straße 17
16321 Bernau · Germany
Phone +49 3338 694265
Fax +49 3338 764440
www.limetec-biotechnologies.de
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Medipan GmbH
Key figures
11 Developing, manufacturing and distributing in vitro-
diagnostic assays in the field of organ-specific
autoimmunity like thyroid diseases and type 1 diabetes
11 Market leader in type 1 diabetes diagnostic; Inventor
and market leader of the AKLIDES® System, first
system for fully automatic evaluation for cell-based
immunofluorescence tests
11 Currently distributing AKLIDES®-assays for diagnostic
of systemic rheumatic diseases (Hep2-cells, ANCA and
Crithidia)
11 Regarding AKLIDES® as a multiparameter platform
we are developing a bead system (ANA and ANCA
diagnostic) and assays for other indications
11 European distributor of rapid tests (diabetes, liver
function, kidney function, urinary tract infection)
for the use at home
11 Operating worldwide
Market Segments
Major R&D-Topics
11 In vitro-Diagnostics
11 Platform technology of AKLIDES® System
11 Bead assays
Contact
11 ELISA
11 RIA
11 (Digital) IFA (Hep2 cells, ANCA and Crithidia)
11 Bead assays
Medipan GmbH
Ludwig-Erhard-Ring 3
15827 Dahlewitz/Berlin · Germany
Phone +49 33708 4417 0
Fax +49 33708 4417 25
[email protected]
www.medipan.de
Dr. Christina Fritz (Head of Scientific Marketing)
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
- o m ic s T e c hn o lo g ies
1
1
1
1
1
1
1
1
Key figures
Metanomics Health – a BASF Group company – applies
comprehensive Metabolite Profiling (metabolomics) with
biomedical data interpretation. Metabolite Profiling is defined as the parallel analysis of multiple endogenous and
xenobiotic metabolites in biological systems. The core
expertise of Metanomics Health resides in discovery and
validation of biomarkers.
Market Segments
Metanomics Health provides its services to pharmaceutical,
diagnostics and nutrition companies. Technology applications include:
11 Mechanism of action studies
11 Mechanism of toxicity studies
11 Translational and clinical biomarker development
(e. g. PK/PD, patient stratification, efficacy and
safety markers)
11 Companion diagnostic development
11 Cell culture and bioprocess optimization
11 Metabolite profiling platform with more than 75 GC-MS
and LC-MS/MS instruments
11 Wide metabolite coverage via combination of unbiased
and targeted platforms
11 Unique tox mode of action prediction through
MetaMap®Tox database
11 Excellence in systems correlation analysis of complex
gene function relationships
Major R&D-Topics
In cooperation with academic institutes and clinical experts Metanomics Health is running a large-scale diagnostic biomarker program. Areas include metabolic syndrome,
heart failure, prostate cancer and multiple sclerosis to
mention a few.
Contact
Tegeler Weg 33
www.metanomics-health.de
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
MicroDiscovery GmbH
Key figures
11 Foundation: 2000
11 Employees: 16
MicroDiscovery develops software and bioinformatics solutions for diagnostics, personalized medicine and molecular
biology research. The portfolio also includes biostatistical
data analysis and data management.
Efficient proprietary algorithms are the basis for customer
specific software for in vitro-diagnostics and medical technology. Software solutions can be developed as CE-certified,
FDA compliant (21 CFR part 11) and ISO 62304-compliant.
MicroDiscovery is DIN ISO 9001:2008 certified by TÜV
Rheinland.
major R&D-Topics
Market Segments
11 Bioinformatics
11 Software development for in vitro-diagnostics and
11 Development of multiparameter diagnostics
11 Biomarker in complex diseases
11 Systems biology for medical applications
biomedical instruments
11 Data analyses for clinical and biological requirements
11 Software development:
Customer-specific OEM software development,
algorithm development as well as biochips analysis
software
11 Data analysis:
NGS/HTS data analysis service and data mining
11 Biostatistical analysis:
Evaluation of clinical studies, assay validation and
biomarker validation
11 Data management:
Database development and data integration
Contact
MicroDiscovery GmbH
Marienburger Straße 1
www.microdiscovery.de
Dr. Arif Malik
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
11 Foundation: 1999
11 Employees: 15
Minerva Biolabs GmbH is a leading biotechnology company for the development and production of molecular
PCR-based IVD diagnostic and research kits for the detection of microbial contamination in biopharmaceuticals and
cell cultures and human pathogens. In addition we offer a
broad range of testing procedures and elimination services
for the pharmaceutical and biotechnology industry. Our
company is based in Berlin and operates worldwide via
numerous distributors.
To secure customers confidence, Minerva Biolabs has
designed a strict quality management system that meets all
requirements of the worldwide accepted quality standards
ISO 9001 and ISO 13485.
Market Segments
11 Molecular biology
11 Microbiology
11 Diagnostics
11 Contamination control
11 Contamination control: Detection and elimination
of microbiological contamination, disinfection
11 Clinical diagnostics
11 Water diagnostics
11 PCR supplements
11 Enzymes
11 Genomic DNA extracts
11 Quantification standards
Major R&D-Topics
Development and production of qPCR assays and
applications in molecular biology.
Contact
Köpenicker Straße 325, Haus 12
Phone +49 30 2000 4370
Fax +49 30 2000 4379
[email protected]
www.minerva-biolabs.com
Dr. Dirk Vollenbroich (CEO)
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
11 Foundation: 2001
11 Employees: 10, PhD: 3
Market Segments
Synthesis technology made in Germany
peptides&elephants – We serve Peptides – for your p
erfect
satisfaction with quality, price and support. Our major
PEP-LIPS products are high parallel customized peptide
libraries and peptide pools. PEP-LIPS are approved for
T‑Cell Stimulation Assays, Epitope Mapping, EliSpot Assays,
Drug Discovery and Array Technology. The full range of
Peptides and Peptidomimetica from the single to millions
from linear to cyclic from short to overlong, from crude to
high purity, from modified to labeled, from natural to non
natural amino acids – peptides&elephants are your faithful
partner.
Contact
Am Mühlenberg 11
Phone +49 331 50570110
Fax +49 331 50570120
[email protected]
www.peptides.de
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
PolyAn GmbH
Key figures
11 Foundation: 1996
11 Employees: 16
PolyAn is specialised in Molecular Surface Engineering
(MSE) and Surface Molecular Imprinting (SMI). PolyAn’s
proprietary MSE-technology platform is used in the production of biochips, microparticles and nanoparticles as
well as membranes. PolyAn’s surface functionalisation optimises the performance of analytical processes by improving the signal-to-noise ratio, the reproducibility and also
enabling new combinations of surface functionality and
base material.
Contact
PolyAn offers a range of surface functionalised consumables for multiplex diagnostics and LifeScience research:
11 Functionalised microarray slides (both glass and plastic)
and 96-well plates with 3D-reactive surfaces for DNA,
aptamere, peptide and protein arrays.
11 Fluorescence encoded PMMA microparticles (beads) for
multiplex bead arrays and other applications. The beads
are adapted to the most commonly used detection
systems, e. g. flow cytometry, image cytometry and
microscopy systems, respectively.
Based on extensive experience in research and development of surfaces PolyAn also offers tailor-made solutions
for specific customer applications, e.g. surface modified
tubes, membranes, sinter and fleece materials, as consumables for a wide range of applications in LifeScience and
other industries.
PolyAn GmbH
Rudolf-Baschant Straße 2
Phone +49 30 912078 0
Fax +49 30 912078 11
[email protected]
www.poly-an.de
Fridtjof Lechhart
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
1
1
1
1
1
1
1
1
Proteome Factory AG
Key figures
11 Foundation: 2000
11 Employees: 7
Proteome Factory is specialized in protein analysis, proteomics and development of multiplex MeCAT – metal
linked immunoassays.
11 Contract research: Amino acid (de novo) sequencing
of proteins & antibodies, protein sequence verification
and identification, characterization of PTMs, SS bridges,
glycopeptides, 2DE and MS-based host cell protein
assays, quality control of proteins and peptides, protein
quantitation
11 Biomarker finding, proteomics, immuno-, phosphor-,
membrane- proteomics: 2DE, itraq, MudPIT etc.
11 Fee-for-Service: 2DE, protein identification, protein
analysis, N-terminal AA sequencing, high resolution
mass spectrometry, nanoLC-ESI-MSMS
11 Development of MeCAT immuno and bioimaging assays
Major R&D-Topics
11 Development of ultra-sensitive MeCAT multiplex assays
for bioimaging and immuno assays
11 R&D in allergy
11 Proteomics
Market Segments
Contact
11 Immunoassay
Proteome Factory AG
Magnusstraße 11
11 Contract research services
www.proteomefactory.com
Dr. Christian Scheler
11 MeCAT – metal coded tagging reagents for ultra-
sensitive multiplex assays of proteins and antibodies
11 FireSilver MS compatible gel silver staining
11 de novo peptide sequencing software Sequit!
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
1
1
1
1
1
1
1
1
Provitro GmbH
Key figures
11 Foundation: 2001
11 Employees: 9
Provitro combines more than ten years of experiences in
commercialisation of cell culture technologies, Tissue
Microarrays and immunohistochemical analyses with the
scientific expertise of the Pathological Institute of the
Charité, Berlin. Based on a quality management system
according to ISO 9001:2008, we provide our customers
not only with high-quality products, CE marked in vitrodiagnostics and state-of-the-art services but also with individual solutions for their specific requests. Provitro collaborates with distributors in UK, Switzerland, Italy, Austria
and Eastern Europe.
Market Segments
Major R&D-Topics
11 Cell biological services
Certified in-process quality control systems (iCon TMA)
verifying the specificity of antibody reaction.
11 Immunohistochemical services
11 Pathomolecular services
Contact
11 Primary cell cultures and cell-type specific culture media
11 Cytokines
11 Immunohistochemical services: Antibody testing
and target validation
11 Tissue microarrays
11 Pathomolecular services
Provitro GmbH
Charitéplatz 1
www.provitro.de
Dr. Manrico Paulitschke (CEO)
Dr. Axel Koepenik (Senior manager of production
and services, QA and sales)
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
1
1
1
1
1
1
1
1
SCIENION AG
Key figures
11 Foundation: 2000
11 Employees: 32
SCIENION is a Berlin and Dortmund-based company offering complete solutions for parallel bioanalytics and high
throughput production/screening of microarrays in genomics and proteomics. The company is a renowned specialist
for ultra low volume liquid handling, particularly for precious and sensitive compounds of biological or chemical
origin. SCIENION’s technology can easily be transferred
from R&D feasibilities to large scale ISO certified high
throughput production.
Market Segments
SCIENION is a life science company well positioned in the
markets of ultra low volume liquid handling systems and
microarray technologies, addressing the dynamically increasing needs for miniaturization and multiplex analyses.
Products and services are targeted mostly for diagnostics,
pharmaceuticals, veterinary, plant and food analytics and
research.
SCIENION offers hardware, consumables and services. The
sciFLEXARRAYERs allow for non-contact and precise drop
spotting in the pico- to nanoliter range – as for tests with
DNA, oligonucleotides, peptides, proteins, antibodies,
glycans or for dispensing cells. Systems and software are
characterized by its versatility, precision and robustness.
SCIENION’s service includes contract array m
anufacturing
and development of tailor-made array applications on
customer specific supports.
Contact
SCIENION AG
Volmerstraße 7 b
Otto-Hahn-Straße 15
44227 Dortmund · Germany
www.scenion.de
Dr. Holger Eickhoff (CEO)
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
11 Foundation: 1992 with 2 scientists
11 Qualified staff of 37 scientists and technicians
11 Biopharmaceutical company with certified quality
management system, DIN EN ISO 9001:2008 and DIN
EN ISO 13485:2003
11 Development and production of ELISAs, Blots and LIAs
for in vitro-diagnostics of infectious and autoimmune
diseases
11 Development and supply of host cell ELISAs for
pharmaceutical companies worldwide, e. g. for purity
control of influenca vaccines
11 European market leader in development and production
of ready-to-use substrates for enzyme mediated
immunoassays like ELISAs, LIAs, dot and chip assays
11 Development and production of protein stabilizers
Market Segments
11 Medical diagnosis laboratories (testkits) and IVD
manufacturers (reagents)
11 OEM production of CE-certified IVDs for various German
distribution companies
11 Distribution of CE-certified LIAs
Contact
11 Production of monoclonal and polyclonal antibodies,
Spreenhagener Straße 1
15754 Heidesee · Germany
purification and labeling
11 Production of recombinant proteins
11 Development of enzyme immunoassays
www.seramun.com
Prof. Dr. Tomas Porstmann
Major R&D-Topics
11 Multiparameter assays
11 Development of polymeric HRP conjugates
11 Development of substrates for protein arrays
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
1
1
1
1
1
1
1
1
SIFIN Institut für Immunpräparate und Nährmedien GmbH Berlin
Key figures
11 Foundation: 1991
11 Employees: 60
The roots of SIFIN GmbH, founded in 1991 and based in
Berlin, go back to the early 19 th century. Under Bismarck it
bore the name “Berliner Impfanstalt” (Berlin Institute for
Vaccinations) and became part of the “Institut für Seuchenschutz” (Institute for the Control of Epidemics), which
became known as the “Staatliches Institut für Immun
präparate und Nährmedien” (State Institute for Immunopreparations and Culture Media) in 1966. In 1992, with
the help of a private investor, the diagnostic divisions were
continued and successfully developed.
Market Segments
11 Health
11 Food
SIFIN GmbH Berlin has many years’ practice in the development and production of in vitro medical devices:
Major R&D-Topics
11 Monoclonal antibodies: We offer partnership in R&D and
production of mabs on a large scale
relevant to veterinary
medicine
11 Test sera for serotyping of E. coli
Contact
11 Bacteriological test reagents based on monoclonal
antibodies, for use in detection and serotyping of
bacterial enteritis pathogens such as Salmonella,
Shigella, Yersinia, E. coli, including enterohaemorrhagic
E. coli (EHEC) and E. coli relevant to veterinary medicine
11 Blood grouping reagents based on SIFIN clones, test
reagents (ready-to-use) and kits used for automated
blood-grouping systems and Serafol® bedside cards
11 Culture media for different applications
11 Contract manufacturing of monoclonal antibodies
(mabs) for use in diagnostics
SIFIN Institut für Immunpräparate
und Nährmedien GmbH Berlin
Berliner Allee 317– 321
Phone +49 30 927030 0
Fax +49 30 927030 30
[email protected]
www.sifin.de
Martina Vasel (Sales Director)
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
11 Foundation: 2004 as a private German stock
corporation
High qualified and experienced team currently consists of
36 employees (18 work on prospective clinical studies and
9 in R&D and ISO 15189 clinical laboratory).
Market Segments
11 Oncogenomics
11 Clinical oncology diagnostics
11 Molecular diagnostics in cancer/blood screening
11 Identification and validation of biomarker
Proprietary products (will be launched in Germany in 2011):
11 DETECTOR C for screening of CRC in asymptomatic
individuals
11 PREDICTOR C for prognosis/progressions-free survival
of diagnosed CRC patients
Technlogies:
11 Data mining
11 Pathology
11 Tissue collection
11 Array-based technology (RNA expression,
SNP profiling and DNA re-sequencing)
Contact
Hermannswerder 20 a
Phone +49 331 2000 200
Fax +49 331 2000 209
Major R&D-Topics
11 Cancer indications: Colorectal, lung, breast and ovarian
cancer
www.signature-diagnostics.de
Prof. Dr. André Rosenthal (CEO)
Dr. Rainer Kramer (CBO)
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Source BioScience imaGenes GmbH
Key figures
11 Launch of diagnostics: 1996
11 Employees: ca. 130
Source BioScience is an international healthcare and life
sciences group with a number of laboratories in the UK,
Ireland and Germany undertaking a range of genomic and
IHC testing.
We undertake work for health services, academic institutions, pharmaceutical companies and biotech companies.
Amongst the services we offer a range of diagnostic services.
Our laboratories are GLP, GCP and CPA accredited and can
handle formalin fixed tissue samples, wax blocks or preprepared slides. We are registered with the UK HTA (Human Tissue Authority) and the UK Care Commission.
Major R&D-Topics
11 Next generation sequencing: Developing NGS-based
11 Immunohistochemistry: Including – HER2,
methods for tumour mutation profiling
11 Cytology
11 Biomarker development
Gastric HER2 and ER/PR
11 Mutation detection: Including – KRAS, BRAF, EGFR,
NRAS, PI3K
11 Blood analysis: Including – CTC’s
(circulating tumour cells), CEC and CYP2D6
11 FISH: Including – HER2, Gastric HER2
(including BDISH) and EGFR
11 HPV testing: Including genotyping and specific
testing for oral cancer
11 Histopathology: Pathologist reporting service using
a panel of 60 UK-based specialist histopathologists
11 Cytogenetics analyses: Detection of chromosome
aberrations across the entire genome
11 Aneuploidy screening: Polar body analysis for IVF
treatments
Contact
Source BioScience
1 Orchard Place
Nottingham NG8 6PX · UK
Phone +44 115 9739056
[email protected]
Source BioScience imaGenes
Robert-Rössle Straße 10 (Haus D 79)
Phone: +49 30 94892440
www.healthcare.sourcebioscience.com
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
1
1
1
1
1
1
1
1
Key figures
11 Foundation: 1992
11 Employees: 27
STRATEC Molecular (former Invitek GmbH) is a member of
the STRATEC Biomedical group and is based in Berlin since
1992. The company is a globally active provider of timesaving proprietary reagent systems for nucleic acid sample
stabilization and purification. In close collaboration with
clients tailored products are developed for both manual
and automated workflows in molecular diagnostics and
biomedical research. As an EN ISO 13485:2003 + AC 2007
and EN ISO 9001:2008 certified company all STRATEC
Molecular products are subject to extensive quality control.
STRATEC Molecular kits are developed and manufactured
in compliance with in vitro-diagnostic EU Directive 98/79/
EC.
Major R&D-Topics
11 DNA/RNA sample management
11 Automation of molecular diagnostic sample preparation
Contact
11 Non-chaotropic chemistry – gentle nucleic acid
sample preparation (more intact DNA)
11 MSB® – Minimal salt binding
(the fastest way to purify DNA fragments)
11 RTP® – Ready to prep
(prefilled lysis tube, reduced hands-on steps)
11 PSP® – DNA sample stabilization
(at RT in stool, saliva or swab samples)
11 InviTrap® – Selective removal of DNA
(pure RNA without DNase digestion)
11 InviMag® – Magnetic beads
(manual and automated DNA/RNA purification)
11 RNAsure® – Viral RNA protection
(stabilization for up to 6 month at RT)
www.invitek.de
Dr. Jens Beator (Managing Director)
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
11 Foundation: 2006
Strix Diagnostics links potent new technologies with the
requirements of medical technology and diagnostics in order
to create innovative and market-focused solutions. Our
expertise in CE-certified multiparameter analysis systems
enables our customers to quickly and efficiently establish
their multiparameter diagnostic application or other multiplex assays in the market. The product portfolio ranges
from innovative microarray scanner and biochip readers to
integrated in vitro-diagnostic units. Customer specific OEM
solutions are based on our tried and tested devices.
Market Segments
Major R&D-Topics
11 IVD devices
11 Multiparameter and multiplex analysis systems
11 Microarrays
11 Forward looking automation and user-friendly
11 Image analysis
ergonomics
11 Classification systems
Contact
11 TLR500, transmitted light microarray reader
11 FR202, cost-efficient fluorescence slide reader
11 FR102 MTP reads arrays in 96-plate wells
11 StrixAluco image acquisition and analysis software
11 OEM development
Cantianstraße 11
Phone +49 30 473722 18
Fax +49 30 473722 16
[email protected]
www.strix-diagnostics.de
Dr. Dieter Beule
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
Surflay Nanotec, founded in October 2008 in Berlin-Adlers
hof, has specialised in the coating of surfaces to functionalise colloidal as well as larger scale materials. The key
technology of the start up with 8 employees is the patentprotected Layer-by-Layer (LbL) technology with charged
polymers (polyelectrolytes). The combination of physicochemical functions and biological properties separated by
nanometre-thick layers allows the unique modification of
the surface. The areas of application are modern separating materials, substance encapsulation, enzyme immobilisation as well as sensory or diagnostic beads. Patents and
expertise together with licensed patents form the basis for
the development of innovative and market-oriented solutions.
Market Segments
11 Molecular diagnostics
Major R&D-Topics
11 Point of care testing (fundamental research)
11 Contrast agents
11 Enzyme immobilization
11 Biocatalysis
11 RNA/DNA technologies
11 Separation and filtration
11 Contrast agents
11 Dyes and pigments
Contact
Products
11 Functionalised beads (LbL Beads)
11 LbL capsules
11 Oligonucleotide beads
11 LbL kits
11 Microbubbles
11 Labeled polymers
Technologies
11 Basic technology: Layer-by-Layer (LbL)-Technology with
charged polymers
11 Functionalization of surfaces
11 DNA/RNA encapsulation technology
Schwarzschildstraße 8
(in the Technology Park at Adlershof)
Phone +49 30 63921764
Fax +49 30 6706919101
[email protected] www.surflay.com
Dr. habil. Lars Dähne (Authorised Manager)
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Key figures
11 Foundation: 1990
11 Employees: >50
TIB MOLBIOL started 1990 as the first German manufacturer of oligonucleotide primers and real time PCR probes
(TaqMan®, SimpleProbe® and LightCycler® hybridization
probes, Molecular Beacons, Scorpions® Primers, LNA containing probes). Our products are used in the fields of life
science research, medical diagnostics, product quality assessment and environmental analysis. Our research unit
has created more than 15,000 customer specific qPCR
and typing assays ([email protected]). Since 2005 we
provide LightMix® Research Use and Diagnostic Kits for
pathogen detection, hematology and cancer targets, clinical chemistry and pharmacogenetics testing and LightSNiP
assays for general SNP typing.
Market Segments
11 Public Research Laboratories / Universities
11 Medical Diagnostic Laboratories
11 Pharmaceutical Industry
Contact
11 Nucleic Acid Synthesis (DNA, LNA, RNA
Eresburgstraße 22 – 23
oligonucleotides)
11 Fluorescence Detection in real time PCR
11 Assay Development
11 OEM production of kits and probes
11 LightMix® real time PCR Kits
11 LightSNiP real time PCR Genotyping Assays
Major R&D-Topics
Design, development and evaluation of novel real time
PCR assays for any type of instrument (charges apply,
please inquire)
www.tib-molbiol.de
Olfert Landt
1
1
1
1
1
1
1
1
Industry
I m m u n oa ssay
H e m ato lo gy
Coag u l at io n
M ic r o bio lo gy
ot he rs
Zentrum für molekulare Onkologie GmbH (Center for molecular Oncology)
Key figures
11 Foundation: 2008
11 Employees: 4
11 Innovative methods for diagnostic and therapy
of tumor diseases
11 Molecular genetics, determination of mutations (K-RAS, EGFR, PCA3, etc.)
11 Markers for early detection of tumor diseases
(Septin9, own projects)
11 Chemosensitivity assay for prediction of chemotherapy
11 Pathology
11 Development of new biomarkers and analytical services
for studies
Contact
11 Mutation analysis by sequencing and real time PCR
Zentrum für molekulare Onkologie GmbH
Im Biotechnologiepark · TGZ 2
11 Mammalian cell culture
11 Methods of a pathology lab
Major R&D-Topics
11 Oncology
11 Biomarker development Phone +49 3371 681 313
Fax +49 3371 681 312
[email protected]
www.molekulare-onkologie.eu
Dr. Kai Schulze-Forster (CEO)
1
1
1
1
1
1
1
1
science
Ba sic R e s e a r ch
Ide n t i f ic at io n a n d Va l i dat io n o f B io m a r k e r s
A ssay D e v e lo p m e nt
T e c hn o lo gy D e v e lo p m e nt
ot he rs
1
1
1
1
1
Key figures
Major R&D-Topics
BAM uses its competences to improve safety in technology
and chemistry through research and development, testing,
analysis, approvals, advice and information. It represents a
co-partner and service provider to industry and commerce,
policy makers and consumers alike.
(1)Quality assurance with immunoassays, better
screening methods for hybridoma selection
Its Working Group (1) Immunochemical Methods
(head: Dr. Rudolf J. Schneider) deals with various antibodybased analytical methods
Its Working Group (2) Fluorescence Spectroscopy
(head: Dr. Ute Resch-Genger) works on the design, characterization and application of functional chromophore systems as well as the design and supply of certified standards,
calibration tools and validation strategies for different fluorescence techniques
Its Working Group (3) Surface and Thin Film Analysis
(head: Dr. Wolfgang Unger) works on the development and
application of methods for surface, thin film and micro
analysis, including Quality Management, reference materials, metrology and standardization (DIN, ISO)
Technologies 1 Platforms 1 Application Fields
(1)Development of immunoassays (ELISA, other
formats), development of antibodies, synthesis of
haptens, conjugation, identity/purity check of
immunochemicals (LC-MS/MS, HR-MS, MALDI-TOF/
MS, fluorescence, NMR, x-ray structure analysis, etc.);
applications in environmental monitoring, clinical/
in vitro-diagnostics
(2)Design and spectroscopic characterization of
functional chromophores and optical probes based on
different types of fluorophores
(3)Surface chemical analysis (XPS, AES, SIMS, FTIR,
WCA) for characterization of biomaterials and
diagnostic tools (functional organic surfaces,
microarrays)
(2)Development of signal amplification and multiplexing
strategies, screening methods for labels, development
of methods for the relative and absolute measurement
of signal-relevant properties of different types of
fluorescent labels and probes
(3)Development of valid methods of surface chemical
analysis, marker free read out of microarrays, selfassembled monolayers
Contact
Branch Adlershof
Richard-Willstätter-Straße 11
(1)Dr. Rudolf J. Schneider
Phone +49 30 8104 1151
[email protected]
(2)Dr. Ute Resch-Genger
Phone +49 30 8104-1134
[email protected]
Branch Fabeckstraße
Unter den Eichen 44-46
12203 Berlin · Gemany
(3)Dr. Wolfgang Unger
Phone +49 30 8104-1823
[email protected]
www.bam.de
science
ot he rs
1
1
1
1
1
Charité Center for Diagnostic and Preventive Laboratory Medicine
Key figures
The Charité Center for Diagnostic and Preventive Laboratory Medicine comprises the disciplines of the Charité –
Universitätsmedizin Berlin active in the field of in-vitro-
diagnostics including pathology, laboratory medicine &
clinical chemistry, microbiology, virology, hygiene, and
forensic medicine. The Center provides a wide range of
services for R&D and comprehends almost all scientific
expertises in the field of in-vitro-diagnostics. The institutes
of pathology, hygiene and forensic medicine also provide
the complete range of services for healthcare. Diagnostic
services of laboratory medicine & clinical chemistry, microbiology, and virology are provided by Labor Berlin Charité
Vivantes GmbH (q.v.).
11 Complex microbial ecosystems in inflammatory bowel
disease; microbial biofilms
11 Epidemiology of nosocomial infections, hantavirus
11 Tissue-based histopathological diagnostics
11 Molecular genetics
11 Biochemistry/Clinical chemistry
11 Cell-based assays
infections
11 Mechanisms and post-mortem diagnosis of sepsis
11 Genetic risk stratification of rheumatic diseases
11 Antibody targeted enzyme prodrug therapies and
immunotoxines
11 Diagnosis of hereditary and acquired thrombophilia
11 DNA/RNA technologies
11 Bioanalytics (Proteome, genome, and glycome analysis)
11 Micobiological/Virological methods
11 Forensic analyses
Major R&D-Topics
The Charité Center for Diagnostic and Preventive Laboratory Medicine aims at the development of new efficient diagnostic processes and the identification of disease causes.
Areas of research include
11 Molecular cancer research (cancerogenesis, new
biomarkers, DNA/RNA-based assays for diagnosis,
therapy and prognosis)
11 Glycome research (new biomarkers for oncology,
autoimmune disease, stem cells)
11 Molecular mechanisms of inflammation
Contact
Charité Center for Diagnostic and
Preventive Laboratory Medicine
Charité – Universitätsmedizin Berlin
Campus Virchow-Klinikum
Augustenburger Platz 1 · 13353 Berlin · Germany
www.charite.de/charite/charitecentren/uebersicht_der_
centren/cc_5_diagnostische_und_praeventive_labormedizin
Prof. Dr. med. Rudolf Tauber (Medical Director)
[email protected]
science
ot he rs
German Institute of Human Nutrition (DIfE) Potsdam-Rehbruecke
Key figures
The mission of the German Institute of Human Nutrition
(DIfE) is to conduct experimental and clinical research in the
field of nutrition and health, with the aim of understanding
the molecular basis of nutrition-dependent d
iseases, and of
developing new strategies for prevention, treatment, and
nutritional recommendations.
A broad spectrum of experimental and epidemiological
methods.
Major R&D-Topics
11 Investigation of the genetic and pathophysiological
basis of insulin resistance and type 2 diabetes
11 Evaluation of the associations between diet, lifestyle,
biochemical, and genetic markers and risk of type 2
diabetes, obesity, cardiovascular diseases and cancer
11 Research on the role of dietary factors in the
pathogenesis of nutrition-dependent diseases
11 Molecular and biochemical characterization of the
sense of taste
11 Elucidation of the influence of gastrointestinal
microbiota on human health
Contact
German Institute of Human Nutrition (DIfE)
Potsdam‑Rehbruecke
Member of the Leibniz Association
Arthur-Scheunert-Allee 114 – 116
14558 Nuthetal · Germany
Phone + 49 33200 88 335
Fax + 49 33200 88 503
[email protected]
www.dife.de
Dr. Gisela Olias
1
1
1
1
1
science
ot he rs
1
1
1
1
1
Fraunhofer Heinrich Hertz Institute
Key figures
Innovations for the digital future in the field of modern communication systems and digital media and services – are
the key concern of all research and development work carried out by the Heinrich Hertz Institute.
The fields of expertise covered by the Fraunhofer Heinrich
Hertz Institute range from optical communication networks,
systems and components, mobile broadband systems, electronic imaging technologies through to broadband inhouse
networks and optical sensor technologies.
Key areas in which the Fraunhofer Heinrich Hertz Institute
works include video and audio coding and transmission, 2D
and 3D image signal processing, mixed reality displays, 3D
displays, human/machine interfaces, information management and photo and video archiving/retrieval, and novel
optical sensors based on our long-standing experience in
optical communication technology.
Life Science R&D-Topics include:
11 Video retrieval and analysis (EDP-assisted comparison
of individual clinical images)
11 Wireless endoscopy
11 Touch-free control of devices in operating theatres
11 Radio sensor networks (e.g. for the capturing of
diagnostic body function data)
11 Photoacustic sensors detecting and measuring traces of
gases
11 Label-free optical sensors for bio analytics (integrated
optical evanescence sensors including optical micro
resonators)
Major R&D-Topics
General Topics are:
11 Communication networks (fixed and wireless)
11 Image processing (modelling, coding, advanced
displays)
11 Cutting-edge interfaces (touchless control systems,
high-end 3D without glasses)
11 Integrated optoelectronic technology
Contact
Fraunhofer Institute for Telecommunications
Heinrich Hertz Institute
Einsteinufer 37
Phone +49 30 31002 427
[email protected]
Michael Witte
science
ot he rs
Key figures
The Fraunhofer IAP specializes in the research and develop
ment of all types of polymer applications. Polymers synthesized from fossil oil as well as biopolymers from renewable
raw materials find their applications.
11 Working areas cover the synthesis of novel polymers,
derivatization of existing biopolymers, chemical
analytics, physical and structure characterization, and
processing
11 Companies and partners are supported in finding
customized solutions for innovative and sustainable
materials, processing aids, and processes
11 Areas of application are manifold, and partners come
from various industries such as electronics and optics,
medicine, pharmacy, cosmetics, and environmental or
waste water technology
Major R&D-Topics
11“Smart” bioresponsive (protein responsive),
biocompatible and thermoresponsive polymers
11 Biomedical surface modification
11 Biofunctional nanoparticles
11 Polymer synthesis, polymerization and modification
Contact
11 Specialized polymers for biomedical applications
11 Nanoparticles with special functions and labels
11 Non-fouling surfaces and biomolecule immobilization
11 Switchable surfaces for cell culture
11 Development and optimization of innovative and
sustainable materials, processing aids and processes
Geiselbergstraße 69
14476 Potsdam-Golm · Germany
www.iap.fraunhofer.de
Dr. Erik Wischerhoff
Phone +49 331 568 1508
[email protected]
1
1
1
1
1
science
ot he rs
Fraunhofer Institute for Biomedical Engineering – Branch Potsdam
Key figures
Fraunhofer IBMT develops products and applications in
cooperation or in contract with the industry. In Potsdam,
the work concentrates on bioanalytics and focuses on the
following topics:
11 Molecular bioanalytics and bioelectronics
11 Nanobiotechnology and nanomedicine
11 Cellular biotechnology and biochips
11 Metabiobanks
11 Cell-free biosynthesis
In agreement with our philosophy ”Technologies that fit
to life“, various micro- and nanosystems are developed as
tools for life sciences and medicine.
Major R&D-Topics
11 Sensor-actor molecules and autonomous biosensors
11 Assay development
11 Biomarker validation
11 Microfluidic systems
11 Biomimetic materials
11 Others: Cell-free protein synthesis, cryophyllic algae
ivD-Platform: Platform for in vitro-diagnostics
11 Applications based on Lab-on-Chip System:
Integration of all steps of a biochemical assay
from sample preparation to analysis
11 Modular platform for development and production
of in vitro-diagnostics
Multiparameter and microarray technologies
11 Suitable for various samples and matrices
11 Support on materials selection, surface treatment
and biomolecule coupling
11 Spotting technologies for preparation of arrays
Readout systems and biosensors
11 Fibre optic biosensor with fluorimetric detection
11 Real time detection, ultra-sensitive and
quantitative readout
11 Fibre optic sensor disposable
11 Label-free detection
11 Electrochemical readout
11 Electrodes
Contact
Fraunhofer Institute for Biomedical Engineering (IBMT)
Am Mühlenberg 13
Phone +49 331 58187 101
Fax +49 331 58187 199
www.ibmt.fraunhofer.de
Dr. Stephanie Schwarz
[email protected]
ivD-Platform
[email protected]
www.ivd-plattform.fraunhofer.de
1
1
1
1
1
science
ot he rs
Humboldt University of Berlin
Research Center ImmunoSciences, Charité Systems Immunology Lab
Key figures
The Systems Immunology Lab was established in the
Department of Biology at the Humboldt University Berlin
in 2002. In winter 2006, it additionally became affiliated
with the newly founded Research Center ImmunoSciences
at the Charité – Universitätsmedizin Berlin. During these
years, the Systems Immunology Lab hosted varying numbers
(5 – 8) of academic staff and graduate students from widely
different scientific backgrounds, ranging from mathematics and physics to biotechnology and molecular genetics.
Research at the Systems Immunology Lab is decidedly
interdisciplinary, including laboratory-based fundamental
science and computational modeling. Projects are carried
out in collaboration with partners in industry, universities
and clinics.
11 Random‑sequence peptide microarray technology
11 Statistical immunoglobulin sequence analysis
11 Semi-automated confocal image processing and analysis
11 Deterministic and stochastic modeling, machine
learning data analysis and optimal control theory
Major R&D-Topics
11 Serological diagnostics of human brain tumors and
renal allograft rejection using random‑sequence
peptide microarrays
11 Development of bioinformatic analysis tools for
identification of mutations relevant to affinity
maturation of antibodies
11 Assessment of dynamic changes in cellular composition
of lymphatic tissue structures by large-scale confocal
imaging and mathematical modeling
Contact
Systems Immunology Lab
Research Center ImmunoSciences
Hessische Straße 3 – 4
[email protected]
www.sysimm.eu
Dr. Michal Or-Guil
1
1
1
1
1
science
ot he rs
IHP gmbh – INNOVATIONS FOR HIGH PERFORMANCE MICROELECTRONICS
Key figures
IHP is an institute of the Leibniz Association. It develops
silicon-based high-frequency technologies, circuits and
systems for the wireless and broadband communication.
The institute employs a staff of 280 people from 20 countries.
IHP develops and runs a platform of 0.25/0.13 µm SiGe
BiCMOS technologies with heterobipolar transistors up to
300 GHz cut-off frequency and additional modules such
as integrated LDMOS and MEMS (microelectromechanical
systems) in the institute’s pilot line. Besides for wireless
and broadband communication, IHP also provides innovations for biotechnology and medicine, aerospace, automotive industry, industrial automation and photonics.
Major R&D-Topics
Contact
IHP GmbH – Innovations for High Performance
Microelectronics/Leibniz-Institut für innovative
Mikroelektronik
Im Technologiepark 25
15236 Frankfurt (Oder) · Germany
Phone +49 335 5625 0
Fax +49 335 5625 300
General Topics are:
[email protected]
www.ihp-microelectronics.com
11 Wireless systems and applications (wireless sensor
Prof. Wolfgang Mehr (Scientific Director)
networks & Gigabit WLAN)
11 RF circuits (integrated mm-wave circuits, broadband
mixed-signal circuits and low power frontends)
11 Technology platform for wireless and broadband
communication
11 Materials for micro- and nanoelectronics
(e. g. for THz devices)
Medical R&D-Topics include:
11 Body area networks for life sciences
11 System development for point of care diagnostics
and telemedicine
11 Sensing and short-range wireless transmission
of medical data up to Gigabit data rates
11 Microelectronic circuits & systems including
embedded BioMEMS
1
1
1
1
1
science
ot he rs
1
1
1
1
1
Max Delbrück Center for Molecular Medicine
Key figures
The Max Delbrück Center for Molecular Medicine (MDC) is a
major biomedical research institute in Berlin. Our mission
is to translate discoveries from basic research into applications to improve the prevention, diagnosis, and treatment
of major human diseases.
11 Scientists, students & technical staff: 1.150
11 Annual institutional budget: € 61 m
11 Annual extramural funding: € 25 m
11 Member of the Helmholtz Association
With a deep knowledge of the molecular basis of disease,
researchers at the MDC are well placed to identify biomarkers and develop new assays and technologies. The MDC
holds patents on biomarkers – e. g. for cardiac diseases,
cancer metastasis and acute kidney injury – which will be
developed in collaboration with third parties into clinical
applications. Close collaboration with the clinics, especially the Charité, facilitates swift translation of the latest
science from bench to bedside.
The technology transfer partner of the MDC is Ascenion
(www.ascenion.de).
Contact
Major R&D-Topics
Max Delbrück Center for Molecular Medicine · Berlin-Buch
Robert-Rössle-Straße 10 · 13092 Berlin · Germany
11 Cardiovascular & metabolic disease
Phone +49 30 9406 3478
11 Cancer
11 Nervous system disorders
[email protected]
www.mdc-berlin.de
Dr. Christina Quensel (Scientific Coordinator)
science
ot he rs
1
1
1
1
1
Functional Protein Analysis Group
Department of Vertebrate Genomics at the Max Planck Institute for Molecular Genetics
Key figures
11 Expertise in identification and validation of (auto)
antibodies as biomarkers for disease classification
11 Pathway analysis and modelling
11 Establishing alternative detection systems
for biomolecules
11 Relative quantification of proteins and post-
translational modifications
11 Immobilisation of biomolecules (DNA, antibodies,
proteins, peptides, small molecules) onto microarrays
11 Generation of low density (up to 1.000 spots)
microarrays, e. g. peptide and reverse protein
microarrays
11 Different types of spotter (e. g. piezo spotter)
11 Biacore instrument
11 Protein-DNA and protein-protein interactions
11 Miniaturisation of protein-based assays
Contact
Major R&D-Topics
11 Determination and characterization of the kinetics of
interactions (assoziation, dissoziation and equilibrium
constant)
11 Serum profiling
11 Pathway analysis with reverse protein microarrays
11 Alternative detection methods for biomolecules in
miniaturized formats
11 Protein interactions
Dr. H. Seitz
Head of Functional Protein Analysis Group
Phone +49 331 58187 208
[email protected]
www.molgen.mpg.de/research/lehrach
Prof. Dr. Hans Lehrach
Director · Head of Department of Vertebrate Genomics
Ihnestraße 63 – 73 · 14195 Berlin · Germany
science
ot he rs
Department of Biomolecular Systems at the Max Planck Institute of
Colloids and interfaces
Key figures
11 Elucidating the role of complex carbohydrates involved
in biological processes of medical relevance
11 Employing molecular tools created by synthetic
chemistry
11 Understanding recognition events involving glycans
that control cell growth, cell differentiation, cell-cell
interactions, bacterial attachment and signaling events
involving the extracellular matrix
Contact
11 Automated oligosaccharide synthesis
Department of Biomolecular Systems at the
Max Planck Institute of Colloids and Interfaces
Arnimallee 22
11 Glycan microarrays
11 Nanoparticles and colloidal polymers
11 development of carbohydrate-based vaccines
11 Serum analysis for carbohydrate-based biomarkers
Major R&D-Topics
11 Development of carbohydrate-based vaccines against
hospital-acquired bacterial infections, fungi and
protozoan parasites
11 Synthesis and biological activity of oligosaccharides,
proteoglycans and glycosylphosphatidylinositols (GPIs)
11 Impact of complex oligosaccharide structures on
inflammatory processes
11 Glycoproteins as diagnostic markers
11 Synthesis of sequence-defined neoglycopolymers and
their use for biomedical applications
Phone +49 30 83859301
[email protected]
Prof. Dr. Peter H. Seeberger (Director · Head of
Department of Biomolecular Systems)
1
1
1
1
1
science
ot he rs
Physikalisch-Technische Bundesanstalt
Working Group 8.32 · Flow Cytometry and Microscopy
Key figures
PTB is the national metrology institute providing scientific
and technical services. The specific tasks of the working
group Flow Cytometry and Microscopy concern the
11 Determination of reference measurement values
for measurands of the complete blood count, i. e.
concentrations of erythrocytes, leukocytes and platelets,
haemoglobin concentration and haematocrit value
11 Measurement of reference values for particle
concentration in suspensions or particle number in
lyophilized samples
11 Development of reference measurement procedures and
reference instruments for cell counting in body fluids
based on flow cytometry and microscopy including
quantification of fluorescence
11 Investigation of flow-cytometric and quantitative
microscopic procedures for quality assessment in
regenerative medicine
11 Quantification of amplification in polymerase chain
reaction (PCR)
11 Accumulation of rare cells applying magnetic activated
cell sorting (MACS) and flow cytometric cell sorting
(FACS)
11 Process development for rare cell detection in body
fluids, e. g. endothelial cells in blood
11 Data analysis and uncertainty determination for flow
cytometric, microscopic and PCR applications
11 Development of microfluidic devices for flow cytometric
analyses
Picture: Photo of a micro-fluidic chip (left) for flow cytometric
identification of immunologically stained T-lymphocytes (right,
Ly-Th/i:T-helper/inducer lymphocytes, Ly-Ts: T-suppressor lymphocytes, M: monocytes). The micro-fluidic chip was developed in
cooperation with the Technical University Berlin, Fachgebiet Mikro- und Feingeräte)
Contact
Physikalisch-Technische Bundesanstalt
Abbestraße 2 – 12
[email protected]
www.ptb.de
Dr. Jörg Neukammer
1
1
1
1
1
science
ot he rs
Technical University of Applied Sciences – Wildau
Key figures
The research interests of the Biosystems Technology Institute focus mainly on the analysis of electrochemical characteristics of biomolecules on metal and carbon electrodes,
sensor developments and the determination of binding affinities of biomolecules and their interactions with modified surfaces.
11 Characterization of conductive and switchable polymers
for application as signal transducers in the detection of
bioaffine binding partners
11 Analysis of polymer films for interface applications
of redox enzymes and the detection of heterogeneous
electron transfer processes
11 Development of sensors for free radicals (e. g. NO, O2-)
with protein-modified electrodes
11 Development of multiprotein assemblies on electrodes
for analytical applications
11 Optical and mass-sensitive detection of toxins,
virus and bacteria
11 Utilization of nanoparticles (quantum dots, metal
and silica nanoparticles, carbon nanotubes) for
electrochemical and optical sensors
11 Detection of DNA and DNA-binding with
electrochemical DNA chips
11 Protein chips
11 Voltammetry
11 Surface plasmon resonance (SPR)
11 Quarz crystal microbalance (QCM/QCMD)
11 Ellipsometry, dynamic light-scattering
11 Electrical impedance spectroscopy
11 Fluorescence and FT-IR spectroscopy
Major R&D-Topics
11 Nanoparticle synthesis
11 Enzymatic systems
11 Redox proteins
11 DNA and aptamers
11 Antibody characterization
11 Biosensors
Contact
Technical University of Applied Sciences
Institute of Biosystems Technology
Bahnhofstraße 1
15745 Wildau · Germany
Phone +49 3375 508 456
Fax +49 3375 508 458
[email protected]
www.th-wildau.de/lisdat
Prof. Dr. rer. nat. habil. F. Lisdat
1
1
1
1
1
science
ot he rs
University of Applied Sciences Lausitz · Department of Biotechnology
Key figures
The Lausitz University of Applied Sciences was founded in
1991 as a classical engineer education center and has a
strong tendency in scientific research. “In vitro-diagnostics
and bio analytics” was taken up in 2000 and is well integrated in the Lausitz University concept as a main research
topic in medical diagnostics, biotechnology and life science.
11 Assay and technology development
11 Bead-based protein and nucleic acid analysis
Contact
11 Chemo/biosensors and corresponding technologies
11 Protein modification and purification
11 Image-based detection of autoimmune antibodies
11 Cultivation and manipulation of primary cell cultures
11 Cell lines designed for screening and production
purposes
Major R&D-Topics
11 Assay development
11 Multiplex bead PCR/Hybridization array
11 Cell- and bead-based diagnostic assays for autoimmune
diseases
11 Automatic identification of infection patterns of bacteria
11 In vitro and in vivo citrullination and purification
of protein antigens
11 Design of cell lines suitable for screening
of musculoskeletal tissue diseases
11 Enzymatics and assays for citrullination, folding and
protein degradation
11 Electrochemical chemotransistors as transducers
for biosensors
11 SPR-biosensors with internal referencing
11 Cell lines with targeted overexpression of various
autoantigens – EXPRESS platform
University of Applied Sciences Lausitz
Department of Biotechnology
Grossenhainerstraße 57
01968 Senftenberg · Germany
Phone +49 3573 85 910
www.hs-lausitz.de
[email protected]
Prof. Dr. Christian Schröder
1
1
1
1
1
science
ot he rs
The University of Potsdam is the major university in the
federal state Brandenburg. Within the Potsdam research
network “pearls” the university is linked to over 20 research facilities in the greater area of Potsdam.
At the university’s Institute of Biochemistry and Biology
the following workgroups do research in the field of in
vitro-diagnostics and bioanalytics:
The research group “Integrated Protein Chips for Point of
Care Diagnostics – iPOC” (head: Dr. habil. Axel Warsinke)
developed a platform technology for small and fast protein
microarrays, which later can be used in hand-held units in
a medical practice for example.
The research group “Antibody-Technologies” (head: Dr. Katja
Heilmann) works on new immunization and selection strategies for the production of monoclonal antibodies. For that
a work station for the retrieval of monoclonal antibodies is
available.
The research group “Analytical Biochemistry” (head: auxilary Prof. Dr. Ulla Wollenberger) works on the development
of applications of bioanalytical systems. Direct electron
transfer and electrode design for direct protein electrode
communication are studied using cytochromes, oxygenases, peroxidases and molybdoenzymes. Molybdoenzymes
are studied in collaboration with the group “Molecular
Enzymology” (head: Prof. Dr. Silke Leimkühler).
Work station for the retrieval of monoclonal antibodies.
Photo: University Potsdam/Fritze
Contact
Am Neuen Palais 10
Phone +49 331 977 1474
[email protected]
Birgit Mangelsdorf (Spokesperson)
Public Relations and Information Service
1
1
1
1
1
The Capital Region Berlin-Brandenburg
Facts, Services, Strategic Business Advantages
More for Your Investment
Berlin-Brandenburg offers investors the best financial support available in Europe. Investment subsidies are granted in the form of direct payments. The support programs created for these measures
combine funds from the EU, the German federal government and the states of Berlin and Brandenburg. Large companies in the capital region can receive investment subsidies of up to 30 percent,
while medium-size companies receive up to 40 percent and small companies up to 50 percent.
1
High Quality of Living
The region combines the international flair of the Berlin metropolis with the charming countryside
and historical treasures of the state of Brandenburg. The capital region also has a vibrant club scene, a
long list of major cultural events, more than 170 museums, 150 stages and 500 palaces, churches and
parks. Recreational activities such as golf, horseback riding, water sports and aviation are just some
of the wide variety of activities to choose from. The overall cost of living, working and commuting is
significantly lower than in other metropolitan regions.
2
Investing Made Easy
The capital region’s two business development agencies, Berlin Partner GmbH and the ZAB Branden
burg Economic Development Board, provide comprehensive support during the setting-up of your
company’s operations in the region: professional, quick, with no red tape, free of charge and confidential.
»» Business Info: Facts and figures on the Berlin-Brandenburg business region
»» Personnel: Support in recruiting and training new staff
»» Real Estate: Assistance in locating property for sale or rent
»» Financing: Guidance on subsidy and financing opportunities
»» Contacts to government agencies, banks, chambers of commerce, associations and
business networks
3
www.brandenburg-invest.com
www.businesslocationcenter.de/lifesciences_en
Berlin-Brandenburg – An attractive location
4
1 Potsdamer Platz 2 Brandenburger Tor 3 Wissenschaftspark Potsdam-Golm 4 Potsdam Park Sanssouci
Zentrum für Molekulare Diagnostik und Bioanalytik
Berlin-Brandenburg
TSB Innovationsagentur Berlin GmbH
Fasanenstraße 85 · 10623 Berlin · Germany
Tel.: +49 30 318622 17 · Fax: +49 30 318622 22
[email protected] · www.zmdb.de
ZukunftsAgentur Brandenburg GmbH
Team Healthcare Industry/Life Sciences
Steinstraße 104 – 106 · 14480 Potsdam · Germany
Tel.: +49 331 6603 000 · Fax: +49 331 6603 840
[email protected] · www.zab-brandenburg.de
Berlin Partner GmbH
Team Life Sciences
Ludwig Erhard Haus
Fasanenstraße 85 · 10623 Berlin · Germany
Tel.: +49 30 39980 0 · Fax: +49 30 39980 239
[email protected] · www.berlin-partner.de
Imprint
© ZMDB Mai 2011
Publisher
Zentrum für Molekulare Diagnostik und Bioanalytik (ZMDB)
TSB Innovationsagentur Berlin GmbH
Fasanenstraße 85 · 10623 Berlin • Germany
www.zmdb.de
Designsupiran.de
Proofreader Yvonne Frank, Berlin
Printschlesener.de
PhotosPotsdamer Platz: Matthias Fischer
Brandenburger Tor: Berlin Partner/FTB-Werbefotografie
Wissenschaftspark Potsdam-Golm: Lutz Hannemann
Potsdam Park Sanssouci: Böttcher_PTM

In vItro-DIagnostIcs - Zentrum für Molekulare Diagnostik und

Transcription

Similar documents

Chemotherapeutika gegen Influenza